

Press release



LABOMAR GROUP: REVENUES GROW IN 2025 TO EURO 135 MILLION (+34%)

Pro-forma* Adjusted EBITDA of Euro 27 million, with 60% of revenues generated on international markets. Group positions as one of Europe's most diversified nutraceutical CDMO platforms, with manufacturing presence in Italy, Spain, Finland and Canada.

Istrana (TV), 08.06.2026 – Labomar SpA, a leading international nutraceutical CDMO platform specializing in the research, development and contract manufacturing of food supplements, pharmaceuticals, medical devices, foods for special medical purposes and functional cosmetics, announces the 2025 consolidated results, which present **pro-forma* revenues of Euro 135 million (+34%)**, up from Euro 101 million in FY 2024, and **pro-forma* Adjusted EBITDA growth to Euro 27 million**.

The overall performance reflects the full maturity of an integrated industrial model, built over recent years through complementary acquisitions now operating as a single system. The Group is engaged throughout the entire CDMO (Contract Development and Manufacturing Organization) value chain, from the research and development of formulations to the production of plant extracts, from nutraceutical manufacturing to distribution on regulated markets, with operative production capabilities in Italy, Canada, Spain and Finland and specialized expertise in three product segments: food supplements, medical devices and functional cosmetics. The **entry of the Finnish company Pharmia Holding Oy** in October 2025 completes the Group's coverage of the probiotics segment, establishing a strategic position on the Nordic and Baltic markets, which are among the fastest growing in Europe's nutraceutical sector.

*"2025 was a year of strong consolidation and integration for us" stated **Labomar founder and Chief Executive Officer Walter Bertin**. "In just a few years we have built a European CDMO platform with wide-ranging capabilities in nutraceuticals, medical devices and functional cosmetics, covering different but complementary markets through a single industrial model. The operational foundation is solid, with the integration of the acquisitions advancing significantly, while international customers consider us a reliable partner throughout the entire value chain. The 2025 results confirm that the model works and that the growth trajectory is structural".*




In 2025, **60% of revenues** were generated on foreign markets, demonstrating the Group's solid international development. The now established presence in Europe and North America has been extended by further strengthening in the Nordic and Baltic countries in particular, bolstered by the integration of Pharmia Holding Oy. The Group also laid the groundwork in the year to enter new markets in Asia - including China, Vietnam and India - through participation in major international trade fairs in the Far East, fostering the establishment of new contacts and partnerships, within a strategic environment that is highly receptive to European products. In this context, the Labomar Group currently has **more than 300 customers globally**, testifying to the strength of an industrial model capable of responding effectively to the needs of international partners.

The Labomar Group today has a total of **561 employees**, an increase of **16.4% compared with 2024**, reflecting a growth strategy that continues to prioritize people as a strategic asset, and operates **eight production facilities across Italy, Canada, Spain and Finland**. On the industrial front, it has a total capacity of **40 million nutraceutical units, 5 million softgels packages and 23 million units of topical medical devices**. Lastly, we highlight the **management of 86,000 kilograms of raw materials**, demonstrating the level of engagement throughout the production chain.

The **Research & Development** and **Regulatory** divisions have helped to strengthen the Group's distinctive positioning. The former operates through 34 personnel in 5 laboratories located in Veneto, Umbria, Tuscany, Spain and Finland, where new formulations, patented technologies and stability protocols are developed. The research work has led to a portfolio of **20 patents**, including those registered and in the process of registration, and more than **50 dossiers dedicated to medical devices**. The Regulatory Division, consisting of 11 personnel, on the other hand offers specialized support on international regulations and directives in the nutraceutical and functional cosmetics sectors, also supporting the drafting of the technical files necessary for medical devices to comply with the European Regulation (MDR).

2025 was also marked by major strategic investments to support industrial development and future growth, including the **three-year 10 million plan dedicated to Research & Development**, focused on accelerating innovation and the development of proprietary technologies ready for commercialization, and the entry into operation **of the new L6 logistics hub** at the Istrana (Treviso) site.

It is a 7,000 m² facility that has doubled storage capacity, improved operational efficiency and



strengthened the sustainability of the production system, thanks in part to advanced energy solutions and a photovoltaic system capable of covering more than 80% of the site's energy needs.

Simultaneously, the Group continued to strengthen its production capacity through the **expansion of the Orvieto plant**, a Euro 4.5 million investment that will boost production capacity by more than 50%, consolidating its position in the medical device sector. Further investments included the expansion of the production plant in **Canada**, with the addition of 1,400 m² to double production capacity and integrate new technologies and pharmaceutical forms, further strengthening the Group's offering in terms of innovation, quality and flexibility.

Confirming the strength of the Group's credit profile and the confidence of institutional investors in the strategic plan, a **Euro 120 million bond issue** was completed in the year, **underwritten by Tikehau Capital**, a leading European alternative asset manager. The transaction provides the Group with the resources to continue organic and acquisition-led growth, further consolidating its position as Europe's leading CDMO platform.

The company in 2025 continued on its path in the area of sustainability, again publishing the **Group's Impact Report**, reflecting the shared commitment of all companies to report transparently on their activities and mutually beneficial goals.


**i.e. including the effects of the acquisition of Pharmia OY for the entire year.*

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialized in the development and production of food supplements, medical devices, pharmaceuticals, foods for special medical purposes and cosmetics for third parties. Over more than 25 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard.

The Company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Following the acquisitions of Labomar Canada, the Welcare Group, Labiotre Srl and Laboratorios Entema and of Pharmia Holding Oy, in addition to the undertaking of a stake in Sphera, Labomar focused on maximizing the synergies among the various companies, pooling resources and expertise to expand its product portfolio, enter new markets and streamline certain processes, including through the best practices brought by each of the Group companies.



Labomar has been owned since 2023 by Charterhouse Capital Partners, one of the longest-running private equity firms in Europe. With Charterhouse's support, the Group has accelerated its international expansion plan, making strategic acquisitions and building one of the most diversified CDMO platforms in Europe. The partnership has brought a structured governance approach, deal sourcing support, and institutional funding capabilities, factors that have contributed greatly to Labomar's transformation into an international leader.

Labomar whole-heartedly believes in a business system based on sustainability and a real concern for people, the environment and the community. It therefore by 2020 had gained Benefit Company status and later obtained B-Corp™ Certification. This is testament to the Company's decision to join a global movement of enterprises meeting elevated social and environmental impact standards.

For further information:

Labomar Press Office

THANAI Communication Advisors

Thanai Bernardini - +39.335.7245418 - me@thanai.it

Chiara Andretta - +39.347.0682566 - chiara.andretta@thanai.it

Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it